98 related articles for article (PubMed ID: 10823790)
21. Decrease of replicative capacity of HIV isolates after genotypic guided change of therapy.
Sarmati L; Nicastri E; Montano M; Dori L; Buonomini AR; d'Ettorre G; Gatti F; Parisi SG; Vullo V; Andreoni M
J Med Virol; 2004 Apr; 72(4):511-6. PubMed ID: 14981751
[TBL] [Abstract][Full Text] [Related]
22. Maternal 12-month response to antiretroviral therapy following prevention of mother-to-child transmission of HIV type 1, Ivory Coast, 2003-2006.
Coffie PA; Ekouevi DK; Chaix ML; Tonwe-Gold B; Clarisse AB; Becquet R; Viho I; N'dri-Yoman T; Leroy V; Abrams EJ; Rouzioux C; Dabis F
Clin Infect Dis; 2008 Feb; 46(4):611-21. PubMed ID: 18197758
[TBL] [Abstract][Full Text] [Related]
23. Persisting long-term benefit of genotype-guided treatment for HIV-infected patients failing HAART. The Viradapt Study: week 48 follow-up.
Clevenbergh P; Durant J; Halfon P; del Giudice P; Mondain V; Montagne N; Schapiro JM; Boucher CA; Dellamonica P
Antivir Ther; 2000 Mar; 5(1):65-70. PubMed ID: 10846595
[TBL] [Abstract][Full Text] [Related]
24. HIV-1-resistant strains during 8-week on 8-week off intermittent therapy and their effect on CD4+ T-cell counts and antiviral response.
Izopet J; Marchou B; Charreau I; Sauné K; Tangre P; Molina JM; Aboulker JP;
Antivir Ther; 2008; 13(4):537-45. PubMed ID: 18672532
[TBL] [Abstract][Full Text] [Related]
25. Long-term analysis of the resistance development in HIV-1 positive patients treated with protease and reverse transcriptase inhibitors: correlation of the genotype and disease progression.
Václavíková J; Weber J; Machala L; Reinis M; Linka M; Brůcková M; Vandasová J; Stanková M; Konvalinka J
Acta Virol; 2005; 49(1):29-36. PubMed ID: 15929396
[TBL] [Abstract][Full Text] [Related]
26. Differential impact of adherence on long-term treatment response among naive HIV-infected individuals.
Lima VD; Harrigan R; Murray M; Moore DM; Wood E; Hogg RS; Montaner JS
AIDS; 2008 Nov; 22(17):2371-80. PubMed ID: 18981777
[TBL] [Abstract][Full Text] [Related]
27. Predictors of long-term increase in CD4(+) cell counts in human immunodeficiency virus-infected patients receiving a protease inhibitor-containing antiretroviral regimen.
Le Moing V; Thiébaut R; Chêne G; Leport C; Cailleton V; Michelet C; Fleury H; Herson S; Raffi F;
J Infect Dis; 2002 Feb; 185(4):471-80. PubMed ID: 11865399
[TBL] [Abstract][Full Text] [Related]
28. CD4+ cell count 6 years after commencement of highly active antiretroviral therapy in persons with sustained virologic suppression.
Moore RD; Keruly JC
Clin Infect Dis; 2007 Feb; 44(3):441-6. PubMed ID: 17205456
[TBL] [Abstract][Full Text] [Related]
29. Observational study on HIV-infected subjects failing HAART receiving tenofovir plus didanosine as NRTI backbone.
Bongiovanni M; Gianotti N; Chiesa E; Nasta P; Cicconi P; Capetti A; di Biagio A; Matti A; Tirelli V; Marconi P; de Luca A; Mussini C; Gatti F; Zaccarelli M; Abeli C; Torti C; Antinori A; Castagna A; d'Arminio Monforte A
Infection; 2007 Dec; 35(6):451-6. PubMed ID: 18034204
[TBL] [Abstract][Full Text] [Related]
30. Immunovirologic consequences and safety of short, non-structured interruptions of successful antiretroviral treatment.
Sanchez R; Portilla J; Gimeno A; Boix V; Llopis C; Sanchez-Paya J; Merino E; de la Sen ML; Muñoz C; Reus S; Plazas J
J Infect; 2007 Feb; 54(2):159-66. PubMed ID: 16690132
[TBL] [Abstract][Full Text] [Related]
31. Evidence for differences in the sexual transmission efficiency of HIV strains with distinct drug resistance genotypes.
de Mendoza C; Rodriguez C; Corral A; del Romero J; Gallego O; Soriano V
Clin Infect Dis; 2004 Oct; 39(8):1231-8. PubMed ID: 15486849
[TBL] [Abstract][Full Text] [Related]
32. Prolonged CD4+ cell/virus load discordance during treatment with protease inhibitor-based highly active antiretroviral therapy: immune response and viral control.
Sufka SA; Ferrari G; Gryszowka VE; Wrin T; Fiscus SA; Tomaras GD; Staats HF; Patel DD; Sempowski GD; Hellmann NS; Weinhold KJ; Hicks CB
J Infect Dis; 2003 Apr; 187(7):1027-37. PubMed ID: 12660916
[TBL] [Abstract][Full Text] [Related]
33. Drug resistance mutations in HIV-1-infected subjects during protease inhibitor-containing highly active antiretroviral therapy with nelfinavir or indinavir.
Yerly S; Rickenbach M; Popescu M; Taffe P; Craig C; Perrin L;
Antivir Ther; 2001 Sep; 6(3):185-9. PubMed ID: 11808753
[TBL] [Abstract][Full Text] [Related]
34. Sustained CD4 responses after virological failure of protease inhibitor-containing therapy.
Deeks SG; Grant RM
Antivir Ther; 1999; 4 Suppl 3():7-11. PubMed ID: 16021865
[TBL] [Abstract][Full Text] [Related]
35. Progressive multifocal leukoencephalopathy in patients with AIDS receiving highly active antiretroviral therapy.
Tantisiriwat W; Tebas P; Clifford DB; Powderly WG; Fichtenbaum CJ
Clin Infect Dis; 1999 May; 28(5):1152-4. PubMed ID: 10452651
[TBL] [Abstract][Full Text] [Related]
36. Tumor necrosis factor (TNF) system levels in human immunodeficiency virus-infected patients during highly active antiretroviral therapy: persistent TNF activation is associated with virologic and immunologic treatment failure.
Aukrust P; Müller F; Lien E; Nordoy I; Liabakk NB; Kvale D; Espevik T; Froland SS
J Infect Dis; 1999 Jan; 179(1):74-82. PubMed ID: 9841825
[TBL] [Abstract][Full Text] [Related]
37. Discordant outcomes following failure of antiretroviral therapy are associated with substantial differences in human immunodeficiency virus-specific cellular immunity.
Price DA; Scullard G; Oxenius A; Braganza R; Beddows SA; Kazmi S; Clarke JR; Johnson GE; Weber JN; Phillips RE
J Virol; 2003 May; 77(10):6041-9. PubMed ID: 12719595
[TBL] [Abstract][Full Text] [Related]
38. Duration and predictors of CD4 T-cell gains in patients who continue combination therapy despite detectable plasma viremia.
Deeks SG; Barbour JD; Grant RM; Martin JN
AIDS; 2002 Jan; 16(2):201-7. PubMed ID: 11807304
[TBL] [Abstract][Full Text] [Related]
39. Plasma HIV RNA decline and emergence of drug resistance mutations among patients with multiple virologic failures receiving resistance testing-guided HAART.
Tozzi V; Bellagamba R; Castiglione F; Amendola A; Ivanovic J; Nicastri E; Libertone R; D'Offizi G; Liuzzi G; Gori C; Forbici F; D'Arrigo R; Bertoli A; Salvatori MF; Capobianchi MR; Antinori A; Perno CF; Narciso P
AIDS Res Hum Retroviruses; 2008 Jun; 24(6):787-96. PubMed ID: 18507523
[TBL] [Abstract][Full Text] [Related]
40. High frequency of drug resistance mutations in human immunodeficiency virus type 1-infected Korean patients treated with HAART.
Sung H; Jung YS; Kang MW; Bae IG; Chang HH; Woo JH; Cho YK
AIDS Res Hum Retroviruses; 2007 Oct; 23(10):1223-9. PubMed ID: 17961108
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
